Mi Rim Choi
- Molecular Biology
- Oncology top 10%
- Pathology and Forensic Medicine top 5%
- Immunology
- Dermatology top 5%
- Co-authors
- Lee F. AllenGajanan BhatFrancine M. FossKerry J. SavagePoul KnoblauchAndrei R. ShustovAchiel Van HoofSteven M. Horwitz
- Topics
- Acute Lymphoblastic Leukemia research (10 papers)Childhood Cancer Survivors' Quality of Life (9 papers)Histone Deacetylase Inhibitors Research (6 papers)
- Partner nations
- United StatesCanadaPoland
In The Last Decade
Mi Rim Choi
27 papers receiving 640 citations
Hit Papers
Peers
Comparison fields: 5 of 57
- Molecular Biology 268
- Oncology 259
- Pathology and Forensic Medicine 255
- Immunology 177
- Dermatology 118
Countries citing papers authored by Mi Rim Choi
This map shows the geographic impact of Mi Rim Choi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mi Rim Choi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mi Rim Choi more than expected).
Fields of papers citing papers by Mi Rim Choi
This network shows the impact of papers produced by Mi Rim Choi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mi Rim Choi. The network helps show where Mi Rim Choi may publish in the future.
Co-authorship network of co-authors of Mi Rim Choi
This figure shows the co-authorship network connecting the top 25 collaborators of Mi Rim Choi. A scholar is included among the top collaborators of Mi Rim Choi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mi Rim Choi. Mi Rim Choi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 18 | |
| 4 | 4 | |
| 5 | 10 | |
| 6 | 3 | |
| 7 | 3 | |
| 8 | 15 | |
| 9 | 0 | |
| 10 | 4 | |
| 11 | 21 | |
| 12 | Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Studybreakdown → | 386 |
| 13 | 16 | |
| 14 | 3 | |
| 15 | 2 | |
| 16 | 13 | |
| 17 | 19 | |
| 18 | 20 | |
| 19 | 2 | |
| 20 | 2 |
About Mi Rim Choi
Mi Rim Choi is a scholar working on Pediatrics, Perinatology and Child Health, Complementary and Manual Therapy and Biotechnology, having authored 29 papers that have together received 647 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (10 papers), Childhood Cancer Survivors' Quality of Life (9 papers) and Histone Deacetylase Inhibitors Research (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (255 citations), Dermatology (118 citations) and Oncology (259 citations). Mi Rim Choi has collaborated with scholars based in United States, Canada and Poland. Frequent co-authors include Lee F. Allen, Gajanan Bhat, Francine M. Foss, Kerry J. Savage, Poul Knoblauch, Andrei R. Shustov, Achiel Van Hoof, Steven M. Horwitz, Wojciech Jurczak and Jeanette K. Doorduijn. Their work appears in journals such as Journal of Clinical Oncology, Blood and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.